Indiana-based biotech start-up BiomEdit is getting closer to launching a commercial version of its bio-derived probiotic BE-101 that proactively treats necrotic enteritis (NE) in boiler chickens, as the company prepares to launch new products with the help of a fresh round of funding, BiomEdit CEO Aaron Schacht told AgTechNavigator.
Launched in 2022, BiomEdit uses fermentation processes to produce a bacterial therapeutic that expresses molecules that neutralize the key toxin in NE, Clostridium perfringens, Schacht explained. Typically, NE outbreaks are short-lived, but mortality rates can range drastically from 2-50%, according to a Merck veterinary manual.
BE-101 is designed to treat the disease and provide an alternative to traditional antibiotics, impacting a bird’s growth trajectory, he added. BiomEdit administers BE-101 twice – once at hatching and then two weeks following – through a spray on the back of the chick, which is then ingested as the birds peck and preen, Schacht said.
“Anytime the animal has to mount an immune response, they are diverting energy from their primary goal in life, and that’s to produce protein. And so, there’s always some trade-off, even with vaccination,” Schacht elaborated.
The price of BE-101 will be comparable or slightly less expensive than a typical biologic vaccine, Schacht said. “With the combination of the mortality reduction, the feed conversion benefit, and the weight gain, there should be a very good ROI,” he added.
BiomEdit is in the final stages of completing its field safety trials and expects to submit them by the end of May. The start-up expects conditional licensure by the USDA’s Center for Veterinary Biologics in Q3 2026 with commercial readiness by Q4 2026.
BiomEdit navigates the VC funding slump
The biotech start-up is now preparing to raise a Series C, following its $36.5 million Series A round in 2022 and an oversubscribed $18.5 million round Series B round in 2024. BiomEdit will deploy Series C funding to support BE-101’s commercialization and explore treatment of diseases in other animals, like cows, pigs, cats, and dogs, Schacht noted.
BiomEdit weathered the venture capital funding slump by building strong connections with industry leader Ginkgo Bioworks and securing other forms of financing, including $7 million in non-dilutive grant funding from philanthropic organizations like the Bill & Melinda Gates Foundation and Bezos Foundation.
In November 2023, BiomEdit received a $4.5 million grant from the Bill & Melinda Gates Foundation to develop microbiome-based products to reduce the methane emissions from cows, while boosting the livelihoods of small-scale food products in South Asia and sub-Saharan Africa, the company shared in a press release.
“If we hadn’t raised by the end of ... the second quarter in 2022, I don’t know if we’d have gotten the company started,” he said. “The funny thing is everybody thought ’23 would be the bad year until ’24 came along, and then ’24 was going to be the bad year until ’25 came along, and then ’25 wasn’t that great a year.”